Therefore, the study of the effects of PI3K/Akt/mTOR inhibition not only in tumor cells, but in immune cells as well, may lead to selection of treatments that, while efficiently targeting deregulated PI3K/Akt/mTOR signals in tumor cells, preserve normal immune function, for appropriately tuning of personalized cancer therapy. This evidence concerns the gene PIK3CA and cancer.